Giantin mediates Golgi localization of Gal3-O-sulfotransferases and affects salivary mucin sulfation in Sjögren's disease patients.

Sjögren's disease is a chronic autoimmune disease characterized by symptoms of oral and ocular dryness and extra-glandular manifestations. Mouth dryness is not only due to reduced saliva volume but also to alterations in the quality of salivary mucins in these patients. Mucins play a leading role in mucosa hydration and protection, where sulfated and sialylated oligosaccharides retain water molecules at the epithelial surface. The correct localization of glycosyltransferases and sulfotransferases within the Golgi apparatus determines adequate O-glycosylation and sulfation of mucins, which depends on specific golgins that tether enzyme-bearing vesicles. Here, we show that a golgin called Giantin is mislocalized in salivary glands from patients with Sjögren's disease and forms protein complexes with Gal3-O-sulfotransferases (Gal3STs), which change their localization in Giantin knockout and knockdown cells. Our results suggest that Giantin could tether Gal3ST-bearing vesicles and that its altered localization could affect Gal3ST activity, explaining the decreased sulfation of MUC5B observed in salivary glands from patients with Sjögren's disease.

Aberrant MUC1 accumulation in salivary glands of Sjögren's syndrome patients is reversed by TUDCA in vitro.

OBJECTIVES: Xerostomia in SS patients has been associated with low quality and quantity of salivary mucins, which are fundamental for the hydration and protection of the oral mucosa. The aim of this study was to evaluate if cytokines induce aberrant mucin expression and whether tauroursodeoxycholic acid (TUDCA) is able to counteract such an anomaly. METHODS: Labial salivary glands from 16 SS patients and 15 control subjects, as well as 3D acini or human submandibular gland cells stimulated with TNF-α or IFN-γ and co-incubated with TUDCA, were analysed. mRNA and protein levels of Mucin 1 (MUC1) and MUC7 were determined by RT-qPCR and western blot, respectively. Co-immunoprecipitation and immunofluorescence assays for mucins and GRP78 [an endoplasmic reticulum (ER)-resident protein] were also performed. mRNA levels of RelA/p65 (nuclear factor-κB subunit), TNF-α, IL-1ß, IL-6, SEL1L and EDEM1 were determined by RT-qPCR, and RelA/p65 localization was evaluated by immunofluorescence. RESULTS: MUC1 is overexpressed and accumulated in the ER of labial salivary gland from SS patients, while MUC7 accumulates throughout the cytoplasm of acinar cells; however, MUC1, but not MUC7, co-precipitated with GRP78. TUDCA diminished the overexpression and aberrant accumulation of MUC1 induced by TNF-α and IFN-γ, as well as the nuclear translocation of RelA/p65, together with the expression of inflammatory and ER stress markers in 3D acini. CONCLUSION: Chronic inflammation alters the secretory process of MUC1, inducing ER stress and affecting the quality of saliva in SS patients. TUDCA showed anti-inflammatory properties decreasing aberrant MUC1 accumulation. Further studies are necessary to evaluate the potential therapeutic effect of TUDCA in restoring glandular homeostasis in SS patients.

Sedation-analgesia with propofol and remifentanil: concentrations required to avoid gag reflex in upper gastrointestinal endoscopy.

BACKGROUND: The purpose of this study was to identify optimal target propofol and remifentanil concentrations to avoid a gag reflex in response to insertion of an upper gastrointestinal endoscope. METHODS: Patients presenting for endoscopy received target-controlled infusions (TCI) of both propofol and remifentanil for sedation-analgesia. Patients were randomized to 4 groups of fixed target effect-site concentrations: remifentanil 1 ng•mL (REMI 1) or 2 ng•mL (REMI 2) and propofol 2 µg•mL (PROP 2) or 3 µg•mL (PROP 3). For each group, the other drug (propofol for the REMI groups and vice versa) was increased or decreased using the "up-down" method based on the presence or absence of a gag response in the previous patient. A modified isotonic regression method was used to estimate the median effective Ce,50 from the up-down method in each group. A concentration-effect (sigmoid Emax) model was built to estimate the corresponding Ce,90 for each group. These data were used to estimate propofol bolus doses and remifentanil infusion rates that would achieve effect-site concentrations between Ce,50 and Ce,90 when a TCI system is not available for use. RESULTS: One hundred twenty-four patients were analyzed. To achieve between a 50% and 90% probability of no gag response, propofol TCIs were between 2.40 and 4.23 µg•mL (that could be achieved with a bolus of 1 mg•kg) when remifentanil TCI was fixed at 1 ng•mL, and target propofol TCIs were between 2.15 and 2.88 µg•mL (that could be achieved with a bolus of 0.75 mg•kg) when remifentanil TCI was fixed at 2 ng•mL. Remifentanil ranges were 1.00 to 4.79 ng•mL and 0.72 to 3.19 ng•mL when propofol was fixed at 2 and 3 µg•mL, respectively. CONCLUSIONS: We identified a set of propofol and remifentanil TCIs that blocked the gag response to endoscope insertion in patients undergoing endoscopy. Propofol bolus doses and remifentanil infusion rates designed to achieve similar effect-site concentrations can be used to prevent gag response when TCI is not available.

Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular proliferation and high concentrations of EGFR and CD44v5.

Membranous CD44v6 levels in tumors and surrounding samples obtained from 94 patients with squamous cell lung carcinomas were studied and compared to clinical stage, cellular proliferation, membranous CD44v5 levels, epidermal growth factor receptor EGFR and cytoplasmatic concentrations of CYFRA 21.1. CD44v6 positive values were observed in 33/38 non-tumor samples and in 76/94 tumor samples, but there were not statistically significant differences between both subgroups. In CD44v6 positive tumor samples, CD44v6 was not associated with clinical stage, histological grade, ploidy and lymph node involvement, but significant association was found with high cellular proliferation. Likewise, CD44v6 positive tumors had significantly higher levels of EGFR and CD44v5. In patients with squamous cell lung carcinomas and clinical stage I, positive CD44v6 cases were associated with the same parameters. Furthermore, positive CD44v5 squamous tumors were associated significantly with histological grade III and lower levels of CYFRA21.1. Our findings support the value of CD44v6 as a possible indicator of poor outcome in patients with squamous lung carcinomas.

[Cytosolic cathepsin D levels in squamous carcinomas of the lung]. / Significado de la concentración citosólica de catepsina D en el carcinoma escamoso de pulmón.

BACKGROUND AND OBJECTIVES: Cathepsin D is an aspartyl proteinase involved in tumoral invasion. The aim of this work was to study cathepsin D cytosolic levels in squamous carcinomas of the lung and their correlation with several clinical and biological parameters. PATIENTS AND METHOD: The study group included 95 squamous lung carcinomas and 38 normal tissue samples from the same patients. Cathepsin D cytosolic concentrations were determined using an immunoradiometric assay (CIS BioInternational. France). EGFR, erbB2 protein, CD44s, CD44v5 and CD44v6 levels at cell surfaces were determined. The clinical stage, histological grade, ploidy and S-phase cellular fraction (SP) were also considered as variables of the study. RESULTS: Cathepsin D cytosolic levels oscillated between 7.7 and 576 (median: 38.8) pmol/mg protein and were lower (p = 0.001) than those observed in 38 normal lung samples from the same patients. When tumors were classified according to different clinical and biological parameters, we noticed that cathepsin D levels were higher in carcinomas with lower proliferation rates and no nodal involvement, reaching statistical significance in both cases. Moreover, when lung carcinomas were classified according to cathepsin D concentrations, tumors with higher cathepsin D concentrations had lower EGFR levels (p = 0.011) and small global SP values (p = 0.025) and DNA index (p = 0.023). Likewise, they were found to be CD44s positive more frequently (p = 0.001) and SP positive less frequently (p = 0.022). CONCLUSIONS: These results lead us to suggest the following: a) in squamous carcinomas of the lung, cathepsin D cytosolic levels are lower than those observed in normal lung samples from the same patients, and b) in this subtype of lung carcinomas, high cathepsin D levels are associated with tumors without nodal involvement, with low proliferation rates, lower EGFR levels, and a reduced positivity for CD44s, pointing to a possible role of this proteinase as a parameter of good outcome.

[Usefulness of cytosolic tissue-type plasminogen activator levels in lung adenocarcinomas]. / Utilidad de la determinación del activador del plasminógeno tipo tisular citosólico en el adenocarcinoma de pulmón.

BACKGROUND: We aimed at studying the behavior of cytosol tissue-type plasminogen activator (t-PA) levels in lung adenocarcinomas and their correlation with other clinical and biological parameters. MATERIAL AND METHOD: t-PA cytosol levels were determined using EIA (Boehringer Mannheim. Germany) in 59 samples of lung adenocarcinoma and in 16 samples of normal lung tissue from the same patients. Cathepsin D, CA125, pS2, hyaluronic acid (HA), free beta subunit of chorionic gonadotropin hormone and neuron specific enolase (NSE) cytosol concentrations were determined. We also determined the concentrations of HA, erbB2 oncoprotein, epidermal growth factor receptor (EGFR), CD44s, CD44v5 and CD44v6 in cell surfaces. The following parameters were considered: clinical stage, ploidy, cellular S-phase fraction and histological grade. RESULTS: In adenocarcinomas, t-PA cytosol levels ranged from 0.1 to 14.6 ng/mg prot. (median, 1.4). These levels were lower than those in normal lung tissue (r, 0.1-18.6; median, 2.95 ng/mg prot.) but did not reach statistical significance. On the other hand, t-PA concentrations decreased as the clinical stage increased and were higher in stage I than stage II-III (p = 0.080) and stage III (p = 0.0622). No significant differences of t-PA levels were observed when the histological grade, ploidy and S-phase were considered. Adenocarcinomas with high t-PA values (> 3.7 ng/mg prot., representing the 75th percentile of the whole group), had lower CA125 (p = 0.015) and erbB2 oncoprotein (p = 0.087) concentrations. CONCLUSIONS: These results suggest that cytosol t-PA levels are negatively correlated with tumor size in lung adenocarcinomas. However, the usefulness of t-PA as a prognostic factor needs to be clarified in further studies.